Adaptation to Spanish and validation of the Rhinitis Control Assessment Test (RCAT) questionnaire

Running title: Adaptation of the RCAT to Spanish

Del Cuvillo A1,*, Sastre J2,3,4,*, Colás C5, Navarro AM6, Mullol J4,7,**, Valero A4,8,**

1 Rhinology & Asthma Unit. Department of Otorhinolaryngology, Hospital Universitario de Jerez, Jerez, Spain
2 Department of Allergy, Fundación Jiménez Díaz, Madrid, Spain
3 Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
4 CIBERES, Instituto de Salud Carlos III, Spain
5 Department of Allergy, Hospital Clínico Lozano Blesa. Instituto de Investigación Sanitaria de Aragón, Zaragoza, Spain.
6 Department of Allergy, Hospital El Tomillar, Dos Hermanas, Sevilla, Spain
7 Rhinology Unit & Smell Clinic, Department of Otorhinolaryngology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS, Universitat de Barcelona, Barcelona, Spain
8 Department of Pneumology and Allergy, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

* These authors contributed equally as first authors
**These authors contributed equally with senior responsibilities

Corresponding author:
Alfonso del Cuvillo
Secretaría de la Unidad de ORL (1ª Planta). Hospital Universitario de Jerez, Ronda de Circunvalación, s/n, 11407 Jerez de la Frontera, Cádiz, Spain
Email: dr.cuvillo@comcadiz.es

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.18176/jiaci.0420
DISCLOSURES:

Dr. Del Cuvillo reports grants from MYLAN, during the conduct of the study; grants and personal fees from MYLAN, personal fees from ALK, personal fees from GSK, grants and personal fees from FAES Pharma, personal fees from MSD, grants and personal fees from Novartis, grants and personal fees from Allakos, grants and personal fees from Sanofi, outside the submitted work.

Dr. Navarro reports grants from MYLAN, during the conduct of the study; personal fees from GSK, personal fees from Leti, personal fees from Chiesi, personal fees from Astra Zeneca, personal fees from Merck, personal fees from MSD, personal fees from Stallergenes, personal fees from ALK, outside the submitted work.

Dr. Valero reports grants from MYLAN, during the conduct of the study; grants and personal fees from ASTRAZENECA, grants and personal fees from NOVARTIS, personal fees from SANOFI, personal fees from MYLAN, personal fees from MUNDIPHARMA, personal fees from LETI, personal fees from CHIESI, personal fees from GSK, outside the submitted work.

Dr. Colás Sanz reports grants from MYLAN-MEDA Pharma, during the conduct of the study; personal fees from GlaxoSmithKline, personal fees from Novartis, personal fees from AstraZeneca, personal fees from Menarini Group, outside the submitted work.

Dr. Joaquin reports grants from MYLAN, during the conduct of the study; personal fees from MYLAN, grants and personal fees from SANOFI, personal fees from NOVARTIS, personal fees from GSK, personal fees from ASTRA ZENECA, personal fees from LETI, grants from ALK, personal fees from MUNDIPHARMA, outside the submitted work.

Dr. MULLOL reports grants from MYLAN-MEDA Pharma, during the conduct of the study; personal fees from SANOFI-Genzyme-Regeneron, grants and personal fees from MYLAN-MEDA Pharma, grants and personal fees from URIACH Group, personal fees from ALK-Abelló A/S, personal fees from Menarini Group, personal fees from MSD, personal fees from GlaxoSmithKline, personal fees from Novartis, grants and personal fees from UCB Pharma, personal fees from GENENTECH - Roche, outside the submitted work.
Abstract

**Background:** The Rhinitis Control Assessment Test (RCAT) is a widely used patient-based questionnaire developed to evaluate control of rhinitis.

**Objective:** To develop and validate a Spanish version of the RCAT (RCATe).

**Methods:** After translation and cultural adaptation of the original RCAT, this multicentric observational, prospective study evaluated the properties/attributes of the RCATe assessing its validity, reliability, responsiveness, size effect, minimal important difference and cut point score.

**Results:** A total of 252 allergic rhinitis (AR) patients from 27 allergy and otolaryngology departments from hospitals throughout Spain were included. Significant and strong correlations were found between the RCATe and the total nasal symptom score and the visual analogue scale (-0.79 and -0.77, respectively; p<0.0001). The RCATe significantly distinguished between patients grouped in different severity or duration AR categories (p<0.001). The internal consistency (Cronbach alpha) was good (0.84) and the test-retest reliability was moderate (0.54 by the physician and 0.49 by the patient). The RCATe responsiveness to change was high and significant (p<0.0001), and linearly correlated with the improvement of AR. The overall size effect was 1.62. The cut-off point to identify patients with adequate AR control was >20 (ROC curve area= 0.746; sensitivity= 58.3%; specificity= 90.9%).

**Conclusion:** The psychometric evaluation and validation of RCATe indicated good reliability, validity, and responsiveness suggesting it can be effectively used to measure control of AR symptoms by Spanish-speaking patients.

**Key words:** Allergic rhinitis. Patient-reported outcome. Rhinitis control. Psychometric evaluation. Rhinitis Control Assessment Test
Resumen

Antecedentes: El cuestionario de control de la rinitis RCAT (Rhinitis Control Assessment Test) es un cuestionario auto administrado para evaluar el control de la rinitis, de uso muy extendido.

Objetivo: Desarrollar y validar una versión traducida del cuestionario RCAT para pacientes hispanohablantes (RCATe).

Métodos: Tras la traducción y adaptación cultural del cuestionario original, se realizó un estudio multicéntrico prospectivo para evaluar los atributos y propiedades del RCATe analizando su validez, fiabilidad, capacidad de respuesta, tamaño del efecto, diferencias mínimas relevantes y puntos de corte.

Resultados: Se incluyeron 252 pacientes con rinitis alérgica (AR) de 27 unidades de Alergia y Otorrinolaringología de hospitales de toda España. El RCATe, la puntuación total de síntomas y la escala visual analógica se correlacionaron de forma robusta y significativa (-0.79 and -0.77, respectivamente; p<0.0001). El RCATe diferenció de forma significativa pacientes clasificados en diferentes categorías de gravedad o duración de la AR (p<0.001). La consistencia interna (alfa de Cronbach) resultó buena (0.84) y la fiabilidad test-retest moderada (0.54 evaluada por el especialista y 0.49 por el paciente). La sensibilidad al cambio del RCATe fue elevada significativamente (p<0.0001), y se correlacionó linealmente con la mejoría de la AR. El tamaño del efecto global fue 1.62. El punto de corte para identificar pacientes con un adecuado control de la AR fue >20 (área de la curva ROC= 0.746; sensibilidad= 58.3%; especificidad= 90.9%).

Conclusiones: La evaluación psicométrica y la validación del RCATe indicaron una buena fiabilidad, validez y capacidad de respuesta, sugiriendo que puede usarse eficazmente para evaluar el control de los síntomas de AR en pacientes hispanohablantes.

Palabras Clave: Rinitis alérgica, variables informadas por pacientes, control de la rinitis, evaluación psicométrica, cuestionario de control de la rinitis.
Introduction

Allergic rhinitis (AR) is the non-communicable chronic disease with the highest prevalence, affecting approximately one fourth of the world population [1]. AR has a major impact on patient quality of life [2], assessed using standardized questionnaires [3, 4], that is related to the severity of the disease [5]. It has been shown that disease-related indirect and direct costs represent a major burden for health systems [6].

The concept of control of chronic diseases has been introduced in recent decades given the difficulties to reach full remission in affected patients and the need for a new individualized medical care approach, known as precision medicine [7]. Control defines a status in which the treatment objectives are reached, and symptoms are minimized [8]. Disease control comprises various dimensions of the disease such as effects on daily or nocturnal symptoms, on social life, work, academic education or leisure activities. Similarly, it includes the influence on these aspects of the medication and its adverse effects, the impact on respiratory function, the degree of response to treatments, the impact of exacerbations and the prognosis of the disease. In contrast, the concept of disease severity refers to the intensity of the loss of function of the organ/s affected by the disease. Severity is an intrinsic feature of the disease that can change in time.

The evaluation of disease control in AR is challenging due to the difficulty of including all the above dimensions in a single measurement tool. The evaluation of AR control can be performed using standardized questionnaires, in a similar way to the evaluation of control proposed for the management of asthma. These questionnaires are relatively simple and practical tools which allow a fast assessment of disease control by interrogating the patient with a few questions [9]. The Rhinitis Assessment
Control Test (RCAT) is a patient reported outcome composed of 6 Likert-type questions with 5 response options, scoring from 1 to 5, with a total score from 6 to 30 (the higher the score, the better the control) [10]. It was originally validated in American English and then widely validated and translated to some languages [11]. The RCAT is likely the patient-based questionnaire most widely used to assess AR control, especially in clinical research, and it has been positively evaluated with respect to its psychometric qualities and its capacity to evaluate control [9].

The objective of this study was to translate and adapt the RCAT questionnaire for its use by Spanish-speaking patients, as well as to evaluate the psychometric attributes of this translated version, following the recommendations of the international consensus-based standards for the selection of health measurement instruments (COSMIN) [12].

Methods

RCATe translation and cultural adaptation

It was carried out following established procedures through a forward and back translation process [13]. Qualitative assessment was performed by pilot interviews using translated versions of the questionnaire with 11 AR patients from the Hospital Clínico de Zaragoza and the Hospital Clinic de Barcelona, to test readability and comprehensibility.

AR patients

To validate psychometrically the RCATe, a multicentric, observational prospective study in real-life conditions was designed. Allergologists and otolaryngologists from referral hospitals throughout Spain participated in the study. To avoid possible biases, each
physician did not include more than 4 patients per month, up to a total of 15 patients per investigator. Patient inclusion criteria were ≥18 years old diagnosed with moderate to severe AR following the criteria of the modified ARIA Guidelines (mARIA) [14], and with a reflective total nasal symptom score (rTNSS: the sum of a bilateral scoring symptom of nasal congestion/obstruction, nasal itching, rhinorrhea and sneezing, scoring from 0 -no symptom- to 3 -highest intensity-) ≥ 8 (from 0 to 12). Patients excluded were those participating in clinical trials or patients diagnosed with obstructive septal deviation, chronic rhinosinusitis or nasal polyps. All patients signed a written informed consent to participate in the study. The study was approved by the Ethics Committee for Clinical Research of the Hospital Clínic de Barcelona. The study was carried out from November 2015 to October 2016.

**Study design**

The patients were interviewed twice within a month (baseline visit and second visit). Data was collected on demography, concomitant diseases and medication use, etiology of allergic sensitization, severity of rhinitis depending on a symptom score, on the affection of quality of life (ESPRINT Questionnaire) [15] and through visual analogical scales (VAS, 0-10 cm) for global and symptoms severity. Additionally, patients were given the Spanish version of the RCAT questionnaire (RCATe) (Figure 1).

The psychometric validation of the RCATe questionnaire was performed according to the following parameters:

- **Feasibility:** Percentage of patients able to respond to all questions of the RCATe questionnaire.

- **Floor and ceiling effect:** Percentage of patients with the maximum and minimum score.
- Convergent validity: Estimated by computing the Spearman rank-order correlations between the score from the RCAT<sub>e</sub> questionnaire and the rTNSS, and between the RCAT<sub>e</sub> and a global AR severity score assessed by the patient on a VAS.

- Discriminant validity: Assessment of the differences in the RCAT<sub>e</sub> score among patients classified in different categories of the classification of AR according to the modified ARIA Guidelines [14].

- Reliability: Internal consistency was measured using the Cronbach's alpha coefficient and test-retest reliability was measured by the intraclass correlation coefficient (ICC) between the RCAT<sub>e</sub> score at initial and final visits in patients who reported a similar state of health with respect to AR in a specific likert scale question called “change in health status”, asked in the final visit.

- Responsiveness: Relationship between changes in the RCAT<sub>e</sub> score, in initial and final visits, with the degree of improvement in the AR symptoms evaluated by a specific question asked to the patient (“change in health status”) and to the physician, as with the changes in the rTNSS between the initial and final visits.

- Size effect: was calculated as the difference between the means of the RCAT<sub>e</sub> scores of the two visits divided by the standard deviation of the score at the baseline visit.

- Minimally important differences (MID): To calculate the MDI two approaches were used, one based on the distribution of the values and one based on evaluating the relationship between the scores of the instrument and an independent measure (anchor-based) [16]. In the distribution-based approach, the score equivalent to half a standard deviation and a standard error of the
mean (SEM) was considered. The SEM was obtained by multiplying the standard deviation of the scale at the baseline visit by the square root of one minus the reliability coefficient of that scale (Cronbach's α). To calculate the MID according to the anchor-based approach, the means of the RCAT_e score at baseline and final visit were determined, as well as the difference between the two visits, obtained by patients stratified according to the variable ‘change in health status’. The mean change was considered for patients who reported a 'somewhat better' change as MID.

- Cut-off point to discriminate between poorly controlled and well-controlled patients (a second cut-off point for partially controlled): The degree of control according to the physician was used as reference, considering the patient well-controlled when the physician considered that he/she had improved much, while the rest of the categories (somewhat better, same, somewhat worse or much worse) was considered uncontrolled. To evaluate the ability of the RCAT_e questionnaire to classify patients according to the level of control, in the full spectrum of cut-off points (poor control vs. good control), the area under the receiver operating characteristic (ROC) curve was calculated. For each cut-off point, the sensitivity, specificity, positive predictive value, negative predictive value and the percentage of patients correctly classified together with 95% confidence intervals (CI) were calculated. In addition, the percentages of false positives and false negatives were analyzed. The point that allowed maximizing sensitivity, specificity, and positive and negative predictive values was chosen as the cut-off point, using the Youden Index (sensitivity + specificity - 1). In addition, a second cut-off point was calculated to discriminate between
partially controlled patients and not-controlled patients, excluding controlled patients, with the same methodology. Partially controlled patients were defined as those who had ‘somewhat improved’ and not-controlled patients where those who were the ‘equal’, ‘somewhat worse’ or ‘much worse’.

**Statistical Analysis**

We used the SAS software package version 9.2 for Windows for the statistical analysis of the data. We used the mean, standard deviation, minimum and maximum, median (percentile 50th), percentiles 25th and 75th, and the number of valid cases, for the description of continuous variables. For the description of categorical variables, we used the number and percentage of patients by response category. Prior to performing parametric tests, we applied statistical techniques to ensure compliance with the assumptions. In case the established assumptions were not met, non-parametric tests were employed. We used a statistical significance level of p-value <0.05 for all tests.

**Results**

AR patients included in this study (N=252) were selected by 27 allergologists or otorhinolaryngologists working in major hospitals throughout Spain. The age (mean±SD) of the patients was 35±12 years and 71% were women. The time (mean±SD) elapsed between the date of diagnosis and the study was 6.3±9.7 years. Most of the patients presented persistent AR (60%) while the other had intermittent AR. Regarding disease severity, 29.4% presented mild AR, 60.1% moderate, and 10.4% severe. Additionally, 35.7% of the patients had concomitant asthma (34.4% mild, 65.6% moderate) and 60% presented concomitant ocular symptoms.
Feasibility. 99.2% of patients answered 100% of the RCAT_e questions, indicating that the test is viable and easy to understand. The percentage of patients with the minimum and the maximum score was 0 and 1.8%, respectively, suggesting no significant floor or ceiling effects.

Convergent validity was high as suggested by high Spearman correlation coefficients of -0.79 (p <0.0001) between the RCAT_e and the rTNSS, and of -0.77 (p <0.0001) between the RCAT_e and the AR severity assessed using a VAS.

Discriminant validity. Significant differences (p<0.001, Tukey's range test) were found in the RCAT_e score among patients grouped in different categories of the AR classification according to the ARIA Guidelines (Figure 2).

The internal consistency of the RCAT_e was robust, as shown by a Cronbach's alpha coefficient of 0.84. The ICC was 0.49 in the case of patients who assessed their health status as the same, and 0.54 in the case that the assessment of the change in health status was made by the physician.

The responsiveness of the RCAT_e was high, being significantly higher the changes in the RCAT_e for the patients who consider that their health status was much better or much worse compared to those that consider that their health status was equal or somewhat worse or improved (p <0.0001, Tukey's range test). The same if the evaluation of the changes in the health status was made by the physician (Figure 3). The RCAT_e scores (mean ± SD) increased by 9.2±5.1 for the patients for whom AR symptoms were strongly improved, 4.6±4.6 for those who were somewhat improved, 2.6±3.7 for those who were the same, and 2.7±3.5 for those who had somewhat worse, when the evaluation was made by the physician. When this evaluation was made by the patient, the scores on the RCAT_e questionnaire increased by 9.8±5.1
points for those who declared that their state of health at the final visit was strongly improved from the baseline visit, 7.3±5.0 for those that it was somewhat improved, 3.8±3.1 for those that it was slightly improved, 2.9±4.0 for those that it was the same, and -1.6±3.2 points for those that it was somewhat worse. A linear association was observed between the changes in the RCAT_e and the improvement of AR (p <0.001, Tukey's range test). A strong correlation was observed between changes in RCAT_e score and changes in rTNSS, with a correlation coefficient of -0.71 (p <0.0001).

The overall size effect was 1.62. Higher values of effect size were observed in patients with a greater change reported in health status.

The MID calculated by the method of distribution of values was 2.0 points and calculated according to the anchor-based approach was 3.8 points.

Cut off point to discriminate levels of control. The area under the ROC curve was used to assess the capacity of the questionnaire RCAT_e to classify patients according to the level of control, using as reference the degree of control according to the physician (poor control vs. good control). The area under the ROC curve was 0.8106, suggesting good accuracy. The optimal cut-off point obtained to differentiate the controlled patients from the rest was 20 (area under the ROC curve= 0.746; sensitivity= 58.3%; specificity= 90.9%). In addition, a second point was calculated to discriminate between partially controlled patients and uncontrolled patients (excluding controlled patients), which resulted in cut-off of 18 (area under the ROC curve= 0.6646; sensitivity= 69.7%, and specificity= 36.8%).

The correlation between RCATe and the quality of life questionnaire (ESPRINT-15) scores was high and significant (Pearson coefficient=0.85; p<0.0001)
Discussion

This study shows that the psychometric validation of the Spanish version of the Rhinitis Control Assessment test (RCATe) was satisfactory and fulfilled all the requirements established in the COSMIN [12]. The COSMIN brings together the common properties of patient-reported outcome measures (PROs), grouping the nine properties that are considered relevant in any PRO in 3 domains: reliability (which also includes internal consistency and precision), validity (which encompasses the validity of content, criteria and construction, and cultural adaptation), and sensitivity. Here we present favorable results for each of these properties, which show that the RCATe questionnaire has good or very good levels of reliability and sensitivity.

The first psychometric evaluation of the original RCAT questionnaire, although performed on a larger sample, included patients of an age and sex distribution similar to our study [17]. While the Cronbach's alpha coefficient in the Meltzer study and ours was similar (0.84), the test-retest reliability was lower in our study (0.78 versus 0.54 if evaluation was done by the physician or 0.49 if it was done by the patient). It is possible that the difference was due to the inclusion of patients with more types of rhinitis than AR in the first, compared with ours, that included AR exclusively. Additionally, most of the patients in our study improved significantly, being only few the patients who remained unchanged and were available to assess the test-retest reliability.

Regarding convergent validity, the study by Meltzer assessed the correlation of the questionnaire with the rTNSS, the patient's overall assessment of the severity of his rhinitis, and the physician's assessment of the severity and control of the rhinitis. They obtained correlations between -0.3 and -0.6 when the assessment was done by the
patient, but of 0.24 in the case it was done by the physician. In our case, the convergent validity was evaluated against the rTNSS and the overall evaluation of the patient’s severity of AR, obtaining in both cases significant correlation values above 0.70.

With respect to discriminant validity, which is evaluated against known groups, in the study by Meltzer the stratification of severity was performed in mild, moderate and severe, based on the rTNSS, following non-validated criteria. The degree of control was obtained evaluated according to the physician. Questionnaire scores were significantly different among all these groups of patients. In our case, the known groups were established according to the standardized and validated criteria of severity and duration in the modified ARIA guidelines [14]. This resulted in significant and relevant differences in the RCAT\textsubscript{e} score obtained by patients with intermittent or persistent AR, and by patients with mild, moderate, or severe AR.

Longitudinal validity and responsiveness were evaluated in the study by Meltzer by comparing the changes in the questionnaire and changes in the TNSS, in the evaluation of the control by the physician and in the patient’s self-assessment of the change in the disease. A significant improvement was obtained in the RCAT score in patients who improved both according to the physician and according to the patient, but with greater correlation when the evaluation was made by the patient. In our study, a good correlation (>0.70) was obtained between the changes in the RCAT\textsubscript{e} and the change in the rTNSS. We also observed a linear association between the change in the RCAT\textsubscript{e} score and the subjective evaluation of the patient’s change, but this linear association was smaller if the evaluation of the change in AR was performed by the physician. This
aspect coincides in a recurrent way in the two studies, highlighting the character as PRO of all RCAT idiomatic versions.

In the Meltzer study, the optimal cutoff point was established to differentiate between controlled and uncontrolled at the physician's criterion, obtaining the value of 21 from the questionnaire as the one that best discriminates (area under the ROC curve= 0.689, sensitivity= 83%, specificity= 55%). In our case, the optimal value was obtained in 20 (area under the ROC curve= 0.746, sensitivity= 58.3%, specificity= 90.9%), and we calculated a second value for partially controlled patients that resulted in 18. In the original study they obtained a value of 17 for this group of poorly controlled patients.

Finally, the clinical MID in the Meltzer study resulted in 2.2 and 2.4, depending on the approach (based on the distribution or "anchor based"), and in our study the values were similar (2.0 and 3.8, respectively).

Comparing both analyses, the Meltzer study and ours, we can conclude that the psychometric evaluation results were similar and satisfactory. The Spanish version of the questionnaire obtained in our study is suitable according to the quality standards suggested in the COSMIN consensus. In our case we also evaluated some additional features such as the effect size, which turned out to be satisfactory, and the floor and ceiling effects, also reasonable.

The RCAT questionnaire has been translated, adapted and validated psychometrically to other languages, such as Portuguese [18]. Table 1 shows a comparison of the main parameters derived from the original study by Meltzer, the validation of Portuguese version, and our study. The Portuguese adaptation included an objective measurement of nasal function (peak nasal inspiratory flow or PNIF)
which presented a moderate correlation with the RCAT questionnaire (0.52), thus relating control with a measurement of nasal permeability. Strong correlations were also obtained between the Portuguese version of the RCAT and rTNSS, both nasal and extra nasal, as well as a good discriminant validity, with data similar to those obtained in our work. Unfortunately, the Portuguese version of the RCAT did not evaluate sensitivity to change or longitudinal validity.

Control and quality of life are different but related dimensions in the evaluation of the impact of the disease. In our study RCAT\textsubscript{e} and quality of life questionnaire scores (ESPRINT-15) were linearly correlated meaning that a better control of AR is related to a better specific health related quality of life. Both questionnaires can be used in a complementary way when assessing patients with AR.

In conclusion, our study shows that the translated and culturally-adapted version of the RCAT in Spanish (RCAT\textsubscript{e}) shows good psychometric properties, similar to the original and to other versions of the questionnaire, which result in a useful version to evaluate the control of AR in Spanish-speaking patients.

Acknowledgments

The authors thank the participants of this study: María Teresa Dordal Culla (Hospital de Badalona, Barcelona); Encarnación Antón Casas (Hospital Marqués Valdecilla, Santander); Javier Montoro (Hospital Arnau de Vilanova, Valencia); Ignacio Jauregui Presa and Ignacio Antépara (Hospital de Basurto, Bilbao); Manuel Alcántara Villar (private practice, Jaén); Elisa Gómez Torrijos (Hospital Universitario Ciudad Real); Julio Delgado Romero (Hospital Virgen Macarena, Sevilla); Enric Figuerola Massana (Hospital Universitario Juan XXIII, Tarragona); Ramona Soler (Hospital Universitari Son Espases,
Palma de Mallorca); Miguel Armengot Carceller (Hospital General Valencia); María Salas Cassinello (Hospital Carlos Haya, Málaga); Javier Fernández Arbeiza (Complejo Hospitalario, Cáceres); Alfonso Malet Casajuana (Private practice, Malet, Barcelona); Víctor Matheu Delgado (Hospital Quirón, Tenerife); Ruperto González (Clinic Alergocan, Tenerife); José Miguel Villacampa (Hospital de Collado-Villaba-IDC, Madrid); María Cesárea Sánchez (Hospital Juan Ramón Jiménez, Complejo Hospitalario de Huelva); Manuel de Barrio Fernández (Hospital Universitario Gregorio Marañón, Madrid); Ignacio Dávila González (Hospital Clínico, Salamanca); Carmen Panizo Bravo (Hospital Nuestra Señora del Prado. Talavera de la Reina, Toledo); Víctor Soriano Gomis (Hospital General Alicante); María José Barasona Villarejo (Hospital Reina Sofía, Córdoba); José Luis Llorente Pendas and César Alvarez Marcos (Hospital Central Asturias, Oviedo); Jesús Bonnin Otal (Hospital General de Elda, Alicante); Dolores Hernández Fernández de Rojas (Hospital La Fe, Valencia); Francisco Vega de la Osada (Hospital Universitario La Princesa, Madrid); María Luisa González Gutiérrez (Hospital Clínico San Carlos, Madrid); Pedro Amaro Merino (Instituto Oto Vértigo, Madrid); Albert Roger (Centre Roger Asmología y Alergia, Barcelona); Magdalena Lluch Bernal (Hospital Universitario de La Paz, Madrid); Beatriz Parra (Hospital El Bierzo. Ponferrada, León).

The authors thank Francisco López de Saro (Trialance SCCL) for medical writing support.

**Funding:** This study was funded by Meda (a Mylan company)
1. Matricardi PM. The Allergic Epidemic. In: Akdis, C.A., Hellings, P.W., Agache, I. . Global Atlas of Allergic Rhinitis and Chronic Rhinosinusitis. European Academy of Allergy and Clinical Immunology, Zurich, 2015;112–4.

2. Meltzer EO, Gross GN, Katial R, Storms WW. Allergic rhinitis substantially impacts patient quality of life: findings from the Nasal Allergy Survey Assessing Limitations. J Fam Pract. 2012;61:S5-10.

3. Valero A, Alonso J, Antépara I, Baró E, Colás C, Del Cuvillo A, et al. Health-related quality of life in allergic rhinitis: Comparing the short form ESPRINT-15 and MiniRQLQ questionnaires. Allergy. 2007; 62:1372–78.

4. Valero A, Alonso J, Antepara I, Baró E, Colas C, Del Cuvillo A, et al. Development and validation of a new Spanish instrument to measure health-related quality of life in patients with allergic rhinitis: The ESPRINT questionnaire. Value Health. 2007;10:466–77.

5. Mullol J, Bartra J, Del Cuvillo A, Izquierdo I, Muñoz-Cano R, Valero A, et al. Specialist-based treatment reduces the severity of allergic rhinitis. Clin Exp Allergy. 2013;43:723–29.

6. Colás C, Brosa M, Antón E, Montoro J, Navarro A, Dordal MT, et al. Estimate of the total costs of allergic rhinitis in specialized care based on real-world data: the FERIN Study. Allergy. 2017;72:959–66.

7. Hellings PW, Fokkens WJ, Bachert C, Akdis, CA, Bieber T, Agache I, et al. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. Allergy. 2017;72:1297–305.

8. Hellings PW, Fokkens WJ, Akdis C, Bachert C, Cingi C, Dietz de Loos D, et al. Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? Allergy. 2013;68:1–7.

9. Demoly P, Calderon MA, Casale T, Scadding G, Annesi-Maesano I, Brown J, et al. Assessment of disease control in allergic rhinitis. Clin Transl Allergy. 2013;3:7.

10. Nathan RA, Dalal AA, Stanford RH, Meltzer E, Schatz M, Derebery J, et al.
Qualitative Development of the Rhinitis Control Assessment Test (RCAT), an Instrument for Evaluating Rhinitis Symptom Control. Patient. 2010;3:91–9.

11. Nathan RA. The rhinitis control assessment test: Implications for the present and future. Curr Opin Allergy Clin Immunol. 2014;14:13–9.

12. Terwee CB, Prinsen CAC, Chiarotto A, Westerman MJ, Patrick DL, Alonso J, et al. COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study. Qual Life Res. 2018;27:1159–70.

13. Sousa VD, Rojjanasrirat W. Translation, adaptation and validation of instruments or scales for use in cross-cultural health care research: A clear and user-friendly guideline. J Eval Clin Pract. 2011;268–74.

14. Valero A, Ferrer M, Sastre J, Navarro AM, Monclús L, Martí-Guadaño E, et al. A new criterion by which to discriminate between patients with moderate allergic rhinitis and patients with severe allergic rhinitis based on the Allergic Rhinitis and its Impact on Asthma severity items. J Allergy Clin Immunol. 2007; 20:359–65.

15. ESPRINT Study Group: Valero A, Izquierdo I, Sastre J, Navarro AM, Baró E, Martí-Guadaño E, Ferrer M, Dávila I, del Cuvillo A, Colás C, Antépara I, Alonso J, Mullol J. ESPRINT-15 Questionnaire (Spanish Version): Reference Values According to Disease Severity Using Both the Original and the Modified ARIA Classifications. J Invest Allergol Clin Immunol. 2013;23:14-19.

16. Copay AG, Subach BR, Glassman SD, Polly DW, Schuler TC. Understanding the minimum clinically important difference: a review of concepts and methods. Spine J. 2007;7:541–46.

17. Meltzer EO, Schatz M, Nathan R, Garris C, Stanford RH, Kosinski M. Reliability, validity, and responsiveness of the Rhinitis Control Assessment Test in patients with rhinitis. J Allergy Clin Immunol. 2013; 131:379–86.

18. Fernandes PH, Matsumoto F, Solé D, Wandalsen GF. Translation into Portuguese and validation of the Rhinitis Control Assessment Test (RCAT) questionnaire. Braz J Otorhinolaryngol. 2016; 82:674–79.
Table 1. Main parameters obtained in the psychometric validations of the US, Portuguese, and Spanish versions of the RCAT.

| Parameter                              | Meltzer (2012) | Fernandes (2016) | Current study |
|----------------------------------------|----------------|------------------|--------------|
| Patients, N                            | 402¹           | 141²             | 252          |
| Internal consistency (Cronbach’s α)    | 0.85/0.83³     | 0.73             | 0.84         |
| Test-retest reliability                | 0.78/0.84³     | -                | 0.54/0.49⁴   |
| Convergent validity (rTNSS)            | -0.53/-0.59³   | -0.73            | -0.79        |
| ROC cut-off point                      | <21            | 22               | 20           |
| MID                                    | 2.2/2.4⁵       | -                | 2.0/3.8⁵     |

¹ Patients >12 years old with allergic or non-allergic rhinitis.
² Adolescent patients (12-18 years old) with allergic rhinitis.
³ Perennial or seasonal AR, respectively.
⁴ Physician or patient evaluations, respectively.
⁵ Distribution and anchor-based approaches, respectively.

Abbreviations: N=number of patients; MID=minimally important differences; ROC=receiver operating characteristic; rTNSS=reflective total nasal symptom score.
**Figure 1.** Rhinitis control assessment test (RCAT) questionnaire in its original English (left) and Spanish (right) versions.

| Question                                                                 | English                                      | Spanish                                      |
|-------------------------------------------------------------------------|----------------------------------------------|---------------------------------------------|
| 1. During the past week, how often did you have nasal congestion?       | ![English version](image1)                   | ![Spanish version](image2)                 |
| 2. During the past week, how often did you sneeze?                      | ![English version](image3)                   | ![Spanish version](image4)                 |
| 3. During the past week, how often did you have watery eyes?            | ![English version](image5)                   | ![Spanish version](image6)                 |
| 4. During the past week, to what extent did your nasal or other allergy symptoms interfere with your sleep? | ![English version](image7)                   | ![Spanish version](image8)                 |
| 5. During the past week, how often did you avoid any activities (for example, visiting a house with a dog or cat, gardening) because of your nasal or other allergy symptoms? | ![English version](image9)                   | ![Spanish version](image10)                |
| 6. During the past week, how well were your nasal or other allergy symptoms controlled? | ![English version](image11)                  | ![Spanish version](image12)                |

1. Durante la última semana, ¿con qué frecuencia ha tenido congestión nasal?

2. Durante la última semana, ¿con qué frecuencia ha estornudado?

3. Durante la última semana, ¿con qué frecuencia ha tenido los ojos llorosos?

4. Durante la última semana, ¿hasta qué punto sus síntomas nasales o los otros síntomas de alergia han interferido con su sueño?

5. Durante la última semana, ¿con qué frecuencia ha evitado alguna actividad (por ejemplo, ir de visita a una casa donde tienen perros o gatos, cuidar el jardín) a causa de sus síntomas nasales o de los otros síntomas de alergia?

6. Durante la última semana, ¿hasta qué punto han estado controlados sus síntomas nasales o los otros síntomas de alergia?
Figure 2. Boxplots showing the RCAT questionnaire scores (median, 1st and 3rd interquartil values) according to allergic rhinitis duration (A) and severity (B). The differences are statistically significant (p<0.0001, Tukey test) for both comparisons.
Figure 3. Boxplots showing RCAT questionnaire score changes (median, 1st and 3rd interquartile values) between first and second visit for AR patients, according to the improvement evaluated by the physician (A) or the patient (B). The differences are statistically significant (p<0.0001, Tukey test) for both comparisons.